Regenxbio (RGNX) Announces Quarterly Earnings Results, Misses Expectations By $0.93 EPS

Regenxbio (NASDAQ:RGNX) released its quarterly earnings data on Wednesday. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.23 by ($0.93), Bloomberg Earnings reports. The business had revenue of $40.03 million during the quarter, compared to the consensus estimate of $100.00 million. Regenxbio had a net margin of 37.28% and a return on equity of 23.27%.

Shares of NASDAQ RGNX traded down $1.23 during trading hours on Friday, reaching $65.47. 50,977 shares of the stock were exchanged, compared to its average volume of 465,371. The firm has a market cap of $2.26 billion, a P/E ratio of -26.43, a price-to-earnings-growth ratio of 1.83 and a beta of -1.16. Regenxbio has a 52 week low of $19.45 and a 52 week high of $85.10.

In other news, insider Kenneth T. Mills sold 10,000 shares of the stock in a transaction that occurred on Monday, May 21st. The stock was sold at an average price of $47.05, for a total transaction of $470,500.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Donald J. Hayden, Jr. sold 15,000 shares of the stock in a transaction that occurred on Tuesday, May 15th. The stock was sold at an average price of $50.05, for a total value of $750,750.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 72,600 shares of company stock worth $4,033,675. 16.90% of the stock is owned by corporate insiders.

RGNX has been the topic of several research analyst reports. Zacks Investment Research lowered Regenxbio from a “buy” rating to a “sell” rating in a research note on Tuesday, April 17th. BidaskClub upgraded Regenxbio from a “hold” rating to a “buy” rating in a research note on Friday, April 20th. Barclays restated an “overweight” rating and issued a $48.00 price objective (up previously from $38.00) on shares of Regenxbio in a research note on Wednesday, May 9th. Raymond James set a $45.00 price objective on Regenxbio and gave the company a “buy” rating in a research note on Tuesday, May 8th. Finally, ValuEngine upgraded Regenxbio from a “hold” rating to a “buy” rating in a research note on Friday, May 11th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $64.19.

About Regenxbio

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.

Featured Story: Penny Stocks, Risk and Reward Factors

Earnings History for Regenxbio (NASDAQ:RGNX)

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply